Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571049 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine
A Phase 2 study of Rapidly Escalating Migraine, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02571049 is a Phase 2 study of Rapidly Escalating Migraine that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02571049, a Phase 2 study of Rapidly Escalating Migraine, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.
Conditions Studied
Interventions
- DRUG DFN-11
Study Locations (1)
Missouri
- Clinvest - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02571049
The ClinicalTrials.gov registry entry for NCT02571049 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dr. Reddy's Laboratories Limited, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rapidly Escalating Migraine appearing as the primary indexed condition, and to 1 intervention - of which DFN-11 is the first listed.
NCT02571049 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02571049 about?
NCT02571049 is a clinical study titled "Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine". Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.
What is the current status of trial NCT02571049?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-09. Estimated completion is 2016-05.
What conditions does trial NCT02571049 study?
This clinical trial studies the following conditions: Rapidly Escalating Migraine.
What interventions are being tested in trial NCT02571049?
The interventions under investigation include: DFN-11 (DRUG).
Who is sponsoring clinical trial NCT02571049?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02571049 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.